Karyopharm Therapeutics Inc. Earnings Recaps
Q3 2025
Nov 5, 2025
Karyopharm Therapeutics reported a strong Q3 2025, with total revenue rising 13% year-over-year to $44 million, driven by solid performance from its XPOVIO product line and significant advancements in clinical development.
Key takeaways
- Completed enrollment in the pivotal Phase III SENTRY trial for frontline myelofibrosis, with top-line results expected in March and potential to redefine treatment standards.
- Achieved U.S. net product revenue growth of 8.5%, totaling $32 million, reflecting ongoing strength in the multiple myeloma segment.
- Secured approximately $100 million in financing, extending cash runway into Q2 2026 and supporting three core priorities: advancing clinical programs, growing the XPOVIO franchise, and maintaining financial discipline.
Q2 2025
Aug 11, 2025
Karyopharm Therapeutics delivered solid Q2 2025 results, driven by strong commercial performance and significant progress in pivotal Phase III trials, positioning the company for potential transformative outcomes in myelofibrosis and endometrial cancer.
Key takeaways
- Successfully completed enrollment in the Phase III SENTRY trial for myelofibrosis, marking a key milestone in the drug development timeline.
- Positive preliminary safety data for the selinexor and ruxolitinib combination suggests enhanced tolerability compared to ruxolitinib alone.
- Anticipation for top-line results in March 2026, with potential peak revenue estimates of $1 billion annually for selinexor in myelofibrosis in the U.S. market.
- Continued engagement with lenders to enhance liquidity amidst financial constraints, underscoring efforts to maintain operational stability.